2 Oct 2017 07:15
Hardman Research: Demand growing in target markets
Demand growing in target markets - In 2016 Sinclair was transformed into a streamlined, pure-play aesthetics company with a concentrated, competitive portfolio of differentiated injectable products. Effective, longer-lasting, natural looking, minimally invasive treatments are benefiting from trends away from intensive plastic surgery and represent a major growth opportunity. Strong Silhouette sales in the US and Brazil, and declining Sculptra sales are pushing gross margins >70%. Demand in Brazil, the US, and China is set to deliver major value following approvals in the near- and mid-term. In market US demand has lifted InstaLift sales to $2.9m/£2.3m.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/sinclair-pharma-plc-documents/02.10.17-demand-growing-in-target-markets.pdf
To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH | Contacts: Dr Martin Hall mh@hardmanandco.com Dr Dorothea Hill dmh@hardmanandco.com Dr Gregoire Pave gp@hardmanabdco.com Telephone: +44 20 7194 7622 Follow us on Twitter @HardmanandCo |
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Sinclair Pharma (SPH)